BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 30135250)

  • 1. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
    Cho RJ; Alexandrov LB; den Breems NY; Atanasova VS; Farshchian M; Purdom E; Nguyen TN; Coarfa C; Rajapakshe K; Prisco M; Sahu J; Tassone P; Greenawalt EJ; Collisson EA; Wu W; Yao H; Su X; Guttmann-Gruber C; Hofbauer JP; Hashmi R; Fuentes I; Benz SC; Golovato J; Ehli EA; Davis CM; Davies GE; Covington KR; Murrell DF; Salas-Alanis JC; Palisson F; Bruckner AL; Robinson W; Has C; Bruckner-Tuderman L; Titeux M; Jonkman MF; Rashidghamat E; Lwin SM; Mellerio JE; McGrath JA; Bauer JW; Hovnanian A; Tsai KY; South AP
    Sci Transl Med; 2018 Aug; 10(455):. PubMed ID: 30135250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.
    Patel J; den Breems NY; Tuluc M; Johnson J; Curry JM; South AP; Cho RJ
    J Med Case Rep; 2021 Apr; 15(1):252. PubMed ID: 33926553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
    Kim M; Murrell DF
    Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGFβ-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa.
    Knaup J; Gruber C; Krammer B; Ziegler V; Bauer J; Verwanger T
    Anal Cell Pathol (Amst); 2011; 34(6):339-53. PubMed ID: 22002724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.
    Arbiser JL; Fan CY; Su X; Van Emburgh BO; Cerimele F; Miller MS; Harvell J; Marinkovich MP
    J Invest Dermatol; 2004 Oct; 123(4):788-90. PubMed ID: 15373786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa.
    Tartaglia G; Cao Q; Padron ZM; South AP
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa.
    Rami A; Łaczmański Ł; Jacków-Nowicka J; Jacków J
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced expression of insulin-like growth factor-binding protein-3 (IGFBP-3) in Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa.
    Mallipeddi R; Wessagowit V; South AP; Robson AM; Orchard GE; Eady RA; McGrath JA
    J Invest Dermatol; 2004 May; 122(5):1302-9. PubMed ID: 15140235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression.
    Pourreyron C; Cox G; Mao X; Volz A; Baksh N; Wong T; Fassihi H; Arita K; O'Toole EA; Ocampo-Candiani J; Chen M; Hart IR; Bruckner-Tuderman L; Salas-Alanis JC; McGrath JA; Leigh IM; South AP
    J Invest Dermatol; 2007 Oct; 127(10):2438-44. PubMed ID: 17495952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas.
    Illmer J; Zauner R; Piñón Hofbauer J; Wimmer M; Gruner S; Ablinger M; Bischof J; Dorfer S; Hainzl S; Tober V; Bergson S; Sarig O; Samuelov L; Guttmann-Gruber C; Shalom-Feuerstein R; Sprecher E; Koller U; Laimer M; Bauer JW; Wally V
    Br J Dermatol; 2023 Dec; 190(1):80-93. PubMed ID: 37681509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC.
    Martins VL; Caley MP; Moore K; Szentpetery Z; Marsh ST; Murrell DF; Kim MH; Avari M; McGrath JA; Cerio R; Kivisaari A; Kähäri VM; Hodivala-Dilke K; Brennan CH; Chen M; Marshall JF; O'Toole EA
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recessive dystrophic epidermolysis bullosa-associated squamous-cell carcinoma: an enigmatic entity with complex pathogenesis.
    Rodeck U; Uitto J
    J Invest Dermatol; 2007 Oct; 127(10):2295-6. PubMed ID: 17853916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa.
    Rokunohe A; Nakano H; Aizu T; Kaneko T; Nakajima K; Ikenaga S; Matsuzaki Y; Murai T; Tamai K; Sawamura D
    J Dermatol; 2008 Jun; 35(6):336-40. PubMed ID: 18578710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
    Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
    Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptome-Guided Drug Repurposing for Aggressive SCCs.
    Zauner R; Wimmer M; Dorfer S; Ablinger M; Koller U; Piñón Hofbauer J; Guttmann-Gruber C; Bauer JW; Wally V
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma.
    Welponer T; Weber DD; Trattner L; Tockner B; Aminzadeh-Gohari S; Leb-Reichl V; Kaufmann A; Zauner R; Wimmer M; Wally V; Felder TK; Strunk D; Koller U; Bauer JW; Kofler B; Guttmann-Gruber C; Piñon Hofbauer J
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):112-123. PubMed ID: 37669776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
    Faden DL; Thomas S; Cantalupo PG; Agrawal N; Myers J; DeRisi J
    Oral Oncol; 2017 Nov; 74():8-14. PubMed ID: 29103756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas.
    Föll MC; Fahrner M; Gretzmeier C; Thoma K; Biniossek ML; Kiritsi D; Meiss F; Schilling O; Nyström A; Kern JS
    Matrix Biol; 2018 Mar; 66():1-21. PubMed ID: 29158163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High levels of type VII collagen expression in recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma keratinocytes increases PI3K and MAPK signalling, cell migration and invasion.
    Pourreyron C; Chen M; McGrath JA; Salas-Alanis JC; South AP; Leigh IM
    Br J Dermatol; 2014 Jun; 170(6):1256-65. PubMed ID: 24641191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of transforming growth factor-β1 in recessive dystrophic epidermolysis bullosa squamous cell carcinoma.
    Twaroski K; Chen W; Pickett-Leonard M; Tolar J
    Exp Dermatol; 2021 May; 30(5):664-675. PubMed ID: 33595864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.